Clinical Study
Amniocentesis in HIV Pregnant Women: 16 Years of Experience
Table 2
Characteristics of amniocentesis.
| | Characteristics of amniocentesis | Group A
(/%) | Group B
(/%) |
| | Indication | | | | Advanced maternal age | 15/75% | 5/71.4% | | Increased NT | 2/10% | 1/14.3% | | CMV Infection | — | 1/14.3% | | Isoimmunization Rh | 1/5% | — | | Maternal genetic disease (cystic fibrosis) | 1/5% | — | | Malformation | 1/5% | — | | GA (weeks) | | | | 13–15 | — | 1/14.3% | | 16–19 | 13/65% | 4/57.1% | | 19–20 | 1/5% | — | | ≥20 | 6/30% | 2/28.6% | | Chromosomal abnormalities | | | | Trisomy 21 | 1/5% | 1/14.3% | | Viral load at the time of procedure | (copies/
mL) | (copies/
mL) | | <50 | 11/55% | — | | 50–999 | 5/25% | — | | 1000–10000 | 1/5% | — | | >10000 | 3/15% | — | | Unknown | — | 7/100% |
|
|
NT: nuchal translucency; GA: gestational age.
|
